Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allisartan isoproxil/indapamide extended-release - Shenzhen Salubris Pharmaceuticals

Next Previous
X
Search
Drug Profile

Allisartan isoproxil/indapamide extended-release - Shenzhen Salubris Pharmaceuticals

Alternative Names: Indapamide extended-release/Allisartan isoproxil - Shenzhen Salubris Pharmaceuticals

Latest Information Update: 02 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shenzhen Salubris Pharmaceuticals
  • Class Antihypertensives; Indoles; Small molecules; Sulfonamides
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Thiazide-like diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Essential hypertension

Most Recent Events

  • 24 May 2024 Shenzhen Salubris Pharmaceuticals completes a phase-III clinical trial in essential hypertension in China (PO) (NCT06500689)
  • 30 Nov 2023 Pharmacokinetics and adverse events data from the phase I trial released by Shenzhen Salubris Pharmaceuticals
  • 21 Jun 2021 Shenzhen Salubris Pharmaceuticals receives the Notice of Approval of Clinical Trials by National Medical Products Administration to carry out clinical trials of Allisartan Isoproxil/Indapamide sustained-release tablets

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top